• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus - A randomized clinical trial
【24h】

Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus - A randomized clinical trial

机译：补充胆钙化固醇可改善年轻1型糖尿病年轻患者调节性T细胞的抑制能力-一项随机临床试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

It is unknown if cholecalciferol is able to modify defects in regulatory T cells (Tregs) in type 1 diabetes (T1D). In this randomized, double-blind, placebo controlled trial 30 young patients with new-onset T1D were assigned to cholecalciferol (70 IU/kg bodyweight/day) or placebo for 12 months. Tregs were determined by FACS-analysis and functional tests were assessed with ex vivo suppression co-cultures at months 0,3, 6 and 12. Suppressive capacity of Tregs increased (p < 0.001) with cholecalciferol from baseline (-1.59 +/- 25.6%) to 3 (30.5 +/- 39.4%), 6 (44.6 +/- 23.8%) and 12 months (37.2 +/- 25.0%) and change of suppression capacity from baseline to 12 months was significantly higher (p < 0.05) with cholecalciferol (22.2 +/- 472%) than placebo (-16.6 +/- 21.1%). Serum calcium and parathormone stayed within normal range.
机译：尚不清楚胆钙化固醇是否能够改变1型糖尿病（T1D）的调节性T细胞（Tregs）中的缺陷。在这项随机，双盲，安慰剂对照试验中，将30例新发T1D的年轻患者分配为胆钙化固醇（70 IU / kg体重/天）或安慰剂，为期12个月。通过FACS分析确定Treg，并在离体第0、3、6和12个月用离体抑制共培养物评估功能测试，胆钙化醇从基线水平（-1.59 +/- 25.6）升高Tregs的抑制能力（p <0.001）。 ％）增至3（30.5 +/- 39.4％），6（44.6 +/- 23.8％）和12个月（37.2 +/- 25.0％），抑制能力从基线到12个月的变化显着更高（p <0.05 ）的胆碱钙化醇（22.2 +/- 472％）比安慰剂（-16.6 +/- 21.1％）。血清钙和副激素保持在正常范围内。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号